Erythropoietin prevents diabetes-induced podocyte damage

Kidney and Blood Pressure Research

Volumn 31, Issue 6, 2009, Pages 411-415

  Schiffer, Mario ^a   Park, Joon Keun ^a   Tossidou, Irini ^a   Bartels, Janina ^a   Shushakova, Nelli ^a   Menne, Jan ^a   Fliser, Danilo ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b University Medical Center   (Germany)

Author keywords

Akt; Diabetic kidney damage; Erythopoietin; Podocytes

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; JANUS KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DBA MOUSE; DIABETIC NEPHROPATHY; EXPERIMENTAL MODEL; GLOMERULUS FILTRATION RATE; IN VITRO STUDY; KIDNEY INJURY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CELLS, CULTURED; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; JANUS KINASES; MICE; PODOCYTES; POLYETHYLENE GLYCOLS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 57649201070     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000186368     Document Type: Article

References (10)

1. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54:1626-1634
2. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D: Continuous erythropoietin receptor activation affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007;18:2046-2053.
3. Huber TB, Hartleben B, Kim J, Schmidts M, Schermer B, Keil A, Egger L, Lecha RL, Borner C, Pavenstadt H, Shaw AS, Walz G, Benzing T: Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol 2003;23:4917-4928.
4. Foster RR, Saleem MA, Mathieson PW, Bates DO, Harper SJ: Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 2004;288:F48-F57.
5. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP: Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 2001;108:807-816.
6. Schiffer M, Mundel P, Shaw AS, Bottinger EP: A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-β-induced apoptosis. J Biol Chem 2004;279:37004-37012.
7. Bahlmann FH, Song R, Boehm SM, Mengel M, von Waseljewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E, Güler F, Menne J, Haller H, Fliser D: Low-dose therapy with the long-acting erythropoietin analogue darbepoetin-α persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004;110:1006-1012.
8. Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, Kurihara H, Kawachi H, Shankland SJ, Fujita T, Nangaku M: Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007;72:455-463.
9. Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ: Darbepoetin-α protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007;72:489-498.
10. Fliser D, Bahlmann FH, De Groot K, Haller H: Mechanisms of disease: erythropoietin - an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006;3:1-10.